In Brief: Li Medical Technologies
This article was originally published in The Gray Sheet
Li Medical Technologies: Privately held fixation technology firm is developing a new minimally invasive "sutureless suspension approach to bladder neck suspension surgery" for treatment of female incontinence, states Scott Gillis, president, at the March 6 UBS Securities women's health conference in New York City. The Shelton, Connecticut-based firm, which has 12 employees and was founded in 1991, also is developing products for spinal fusion. Its current product, the UltraFix suture anchor, was launched in the U.S. in December 1995 and is used for bladder neck suspension and for sports medicine applications...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.